PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data

Pulse Biosciences is pivoting to its nPulse AFib system following strong clinical results and is ramping investment to accelerate development and future commercialization. The strategic shift and increased R&D/commercial spending position the device as a near-term value driver for the company and could materially affect the stock once clinical and regulatory milestones are confirmed.

Analysis

Pulse Biosciences is pivoting to its nPulse AFib system following strong clinical results and is ramping investment to accelerate development and future commercialization. The strategic shift and increased R&D/commercial spending position the device as a near-term value driver for the company and could materially affect the stock once clinical and regulatory milestones are confirmed.